D-0730-2016 Class II Terminated
FDA drug recall D-0730-2016 was initiated by Genzyme Corporation on Feb 16, 2016 and is designated Class II. Reason for recall: Presence of Particulate Matter: Glass particles found in the product after reconstitution. The recall status is terminated (terminated Mar 2, 2017). Affected quantity: 4669 Cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 9, 2016
- Initiation Date
- Feb 16, 2016
- Termination Date
- Mar 2, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 4669 Cartons
Product description
Thyrogen (thyrotropin alfa for injection), 0.9 mg/mL after reconstitution, For intramuscular injection only, Rx Only, Two vials per Carton, Carton contains 2 vials of Thyrogen, Dilute with Sterile Water for Injection, Storage: store at 2-8 C, Manufactured by: Genzyme Corporation, Northborough, MA 01532 USA, Marketing Authorization holder: Sanofi-Aventis, NDC 58468-0030-2.
Reason for recall
Presence of Particulate Matter: Glass particles found in the product after reconstitution.
Distribution pattern
Nationwide, Puerto Rico and Malaysia, Taiwan, Brazil, and Israel.
Code information
Lot #s: E4029Y03, E4029Y04, E4029Y06, E4029Y07, Exp 12/2017
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0730-2016
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Genzyme Corporation? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.